Joseph S. Dillon, MBA
Chief Executive Officer, Bio-Pact

Joseph S. Dillon, Ph.D., MBA, is Chief Executive Officer of BioPact and brings over two decades of medical industry experience to the BioPact team. Joe is a seasoned executive with extensive experience in global pharmaceutical and biotechnology business strategy and planning, product development, operations, business development and strategic transactions. Most recently, Joe was President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, a strategy and business analytics advisory firm. Prior to that, Joe held senior positions in pharmaceutical management consulting firms, most significantly was as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Joe is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He holds a Ph.D. in Metaphysics, M.B.A. in International Finance and a bachelors in Finance.

Patrick Duxbury
Partner, Gowling WLG International Ltd.

Patrick Duxbury helps clients to research, develop, manufacture and sell pharmaceutical, biotech and medical device products, using his extensive experience of structuring and executing transactions in the life sciences sector.

Patrick was a microbiologist and geneticist before re-qualifying as a lawyer in 1993 with first class honours. He now specialises in all aspects of transactional work in the life sciences sector. He has helped clients including arGEN-X, AstraZeneca, Astellas, MedImmune, Astex Therapeutics, Chroma Therapeutics, Eisai, GlaxoSmithKline (GSK), Heptares Therapeutics, PanGenetics, Prostrakan, SROne and SV Life Sciences on significant M&A transactions, licensing and collaboration deals, fundraisings and associated regulatory issues.

Thanks to his deep knowledge of the world in which he operates, Patrick delivers his clients a unique mix of regulatory, antitrust, IP, corporate and dispute resolution advice, helping many of the sector's key players.

Recent deals include advising AstraZeneca on its $1.275 billion collaboration with Innate Pharma and on its $300 million disposal of the rights to cancer drug Caprelsa. He has also recently advised Heptares Therapeutics Limited and arGEN-X BV on several strategic license and collaboratiosn transactions.

Patrick is a well known speaker on topics relating to transactions in the life sciences sector. He teaches on the BIO Advanced Business Development Course in both the US and Europe.

Kenneth Krisko
Partner, Cooley LLP

Kenneth Krisko is a partner in the Cooley Business department. He joined the Firm in 2000 and splits his time between the Reston and Boston offices.

Mr. Krisko's practice focuses on the representation of public and private life sciences companies in a broad range of commercial and corporate finance matters. He advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including technology licenses and acquisitions, research and development collaborations, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements.

Mr. Krisko also regularly counsels clients on a wide array of corporate and securities matters, including spin-outs, private financings, mergers and acquisitions, public offerings and corporate governance. He works closely with his clients to understand each client's business and strategic objectives and to structure and negotiate transactions to meet those objectives.

Mr. Krisko has been a guest speaker on strategic partnering and corporate issues affecting life sciences companies at various conferences. Mr. Krisko also is an Adjunct Professor of Law at the Georgetown University Law Center where he teaches a course on emerging company legal issues and venture capital finance.

Mr. Krisko received a JD from the University of Virginia School of Law in 1995, where he was a member of the Virginia Law Review. Mr. Krisko received a BS in Aerospace and Ocean Engineering from Virginia Tech in 1987.

Prior to joining Cooley, Mr. Krisko was an associate with Wiley, Rein & Fielding in Washington, DC  Prior to attending law school, Mr. Krisko worked as an engineer for the Department of the Navy.

Mr. Krisko is admitted to practice in the Commonwealth of Virginia, the District of Columbia. He is not admitted to practice in Massachusetts.

Lesley Stolz, Ph.D.
Senior Director, Transactions , Johnson & Johnson Innovation

Lesley is Senior Director of Transactions at Johnson & Johnson Innovation, California.

Lesley has been working in corporate and business development roles for the last 17 years for companies that are both technology platform and therapeutics focused.  Her most recent executive positions have been with BioTime, a publicly traded stem cell technology and therapeutic company, and Sutro Biopharma, a platform technology company working in cell-free protein synthesis. Prior to Sutro, Lesley served in BD positions for a number of biotech companies in the U.S. and Europe.

Lesley received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.